Emergent Biosolutions Price to Free Cash Flow Ratio 2010-2022 | EBS

Historical price to free cash flow ratio values for Emergent Biosolutions (EBS) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Emergent Biosolutions Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2023-01-26 13.12 15.38
2022-09-30 20.99 $0.85 24.61
2022-06-30 31.04 $2.17 14.32
2022-03-31 41.06 $1.34 30.61
2021-12-31 43.47 $1.78 24.47
2021-09-30 50.07 $0.45 111.02
2021-06-30 62.99 $2.24 28.07
2021-03-31 92.91 $5.76 16.13
2020-12-31 89.60 $7.34 12.20
2020-09-30 103.33 $5.06 20.40
2020-06-30 79.08 $3.64 21.72
2020-03-31 57.86 $0.95 61.12
2019-12-31 53.95 $1.93 27.96
2019-09-30 52.28 $-3.34 0.00
2019-06-30 48.31 $-0.10 0.00
2019-03-31 50.52 $1.34 37.59
2018-12-31 59.28 $-0.54 0.00
2018-09-30 65.83 $4.38 15.01
2018-06-30 50.49 $1.94 25.98
2018-03-31 52.65 $2.36 22.27
2017-12-31 46.47 $3.05 15.25
2017-09-30 40.45 $1.09 37.20
2017-06-30 33.91 $0.86 39.52
2017-03-31 29.04 $-0.50 0.00
2016-12-31 32.84 $-0.44 0.00
2016-09-30 31.53 $0.01 2694.87
2016-06-30 26.35 $1.73 15.26
2016-03-31 34.06 $2.42 14.06
2015-12-31 37.49 $-0.05 0.00
2015-09-30 26.70 $0.96 27.82
2015-06-30 30.88 $0.76 40.81
2015-03-31 26.95 $0.73 37.15
2014-12-31 25.52 $1.78 14.31
2014-09-30 19.97 $1.02 19.49
2014-06-30 21.05 $0.38 54.82
2014-03-31 23.68 $0.92 25.76
2013-12-31 21.54 $1.50 14.41
2013-09-30 17.85 $0.04 446.26
2013-06-30 13.51 $-0.04 0.00
2013-03-31 13.10 $-0.50 0.00
2012-12-31 15.03 $-0.07 0.00
2012-09-30 13.32 $1.81 7.36
2012-06-30 14.20 $0.46 30.81
2012-03-31 14.99 $-0.18 0.00
2011-12-31 15.78 $-1.16 0.00
2011-09-30 14.46 $-1.19 0.00
2011-06-30 21.13 $0.68 31.11
2011-03-31 22.64 $1.05 21.48
2010-12-31 21.98 $2.33 9.42
2010-09-30 16.17 $0.55 29.37
2010-06-30 15.31 $-0.08 0.00
2010-03-31 15.73 $1.24 12.64
2009-12-31 12.73 $-0.11 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.671B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.571B 9.49
GSK (GSK) United Kingdom $71.996B 8.97
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.433B 19.52
Ginkgo Bioworks Holdings (DNA) United States $3.414B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.676B 25.16
Biohaven (BHVN) United States $1.305B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.359B 0.00
Ambrx Biopharma (AMAM) United States $0.083B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00